Skip to main content
Caplight Logo









InsuLife

InsuLife

Private
OsloHealthcare & Life Scienceshttps://insulife.com/

Last Round

Debt

Apr 24, 2024

Est. Valuation

$26.13M

Total Funding Raised

$3.28M

Company Overview

InsuLife is a drug discovery company developing a transdermal, needle-free insulin and GLP-1 delivery technology designed for the administration of insulin without injections.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical Devices

Business Model

B2B2C

Customer Profile

Revenue Share, Hardware + Subscription, Government Contracts

AI Layer

Non-AI

Keywords

needle-free insulininsulin spraytransdermal insulintransdermal drug deliverydiabetes treatmentdrug delivery platformspray-on insulinlipid envelope technologyneedle-free GLP-1transdermal GLP-1pharmaceuticalsbiotechnologyclinical trialspreclinical stagepharma licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

InsuLife Comparables

Compare InsuLife with similar companies based on industry and business-model similarity.

InsuLife comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Biotts
74%
Oramed Pharmaceuticals Inc.
74%
NuGen Medical Devices Inc.
72%

InsuLife Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtApr 24, 2024
Early FundingApr 24, 2024
DebtAug 22, 2023
CrowdfundingOct 13, 2022
AcceleratorAug 25, 2020
Grant
Jun 21, 2020

Key People

Founding team and executive leadership

Åge Nærdal

Chief Executive Officer at Insulife AS

Executive Team

Henrik Bruun Andersen

CFO

Executive Team

InsuLife Investors

Notable investors and investment history

InsuLife investors
InvestorRounds
AleapAccelerator
Innovasjon NorgeGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 2, 2025

    Magnus Winterman appointed as new Head of Investor Relations.

  • Oct 2, 2025

    Developing a spray-on-skin insulin delivery system, ILS-2501.

InsuLife Filings

Explore SEC and related filing metadata, where available.

InsuLife filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about InsuLife's valuation, stock price, and market status.

Is InsuLife a public or private company?

InsuLife is a private company.

What is the current stock price of InsuLife?

InsuLife is a private company with no public stock price. No recent secondary market data is available.

How much is InsuLife worth (valuation)?

InsuLife's valuation is estimated at $26.1M based on funding round data.

Can I buy InsuLife stock?

InsuLife shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was InsuLife's last funding round?

InsuLife's most recent funding round was Early Funding on October 13, 2022.

Who are the main investors in InsuLife?

Key investors in InsuLife include Aleap, Innovasjon Norge.

Will InsuLife IPO soon?

No public IPO plans have been announced for InsuLife.

How can I track InsuLife secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor InsuLife's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersOslo
Employee Range8
Year Founded2020
Last FundingApr 24, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?